Active Pharmaceutical Ingredient

Aurobindo Pharma said it 'regularly explores' various strategic opportunities, including potential acquisitions and partnerships, which can enhance shareholder value.

Divi’s Lab: Better capex guidance to meet upcoming demand

R&D activities around peptides and contrast media remain the two medium-term growth drivers for the company. US tariffs are a near-term risk.

Stocks On Radar: HFCL, Waaree Energies, IREDA, Orchid Pharma in focus on 20 February

Join us for the latest stock market update where we cover the key stocks making headlines today. HFCL leads with a groundbreaking agreement under BharatNet Phase-III, while Waaree Energies secures a major solar module supply order. Plus, insights on IREDA and Tata Technologies' new trading contracts, Cyient's executive appointment, Patanjali Foods' legal victory, and Orchid Pharma's recent FDA inspection. Stay informed with our comprehensive overview of today's trading focuses!

Beyond COVID opportunity, what’s in for this Vitamin D API maker?

Fermenta Biotech completed its backward integration project to produce cholesterol which can reduce its cost in the raw material basket from 45 percent to 35 percent

India looks to corner China's API market share; mulls sops to revive old units

The move is aimed at capturing a substantial chunk of API space from China which is currently reeling under trust issues post the outbreak of the ongoing Coronavirus pandemic.

Coronavirus Pandemic | COVID-19 credit neutral for pharma companies for now: Ind-Ra

Furthermore, if the disruption spills beyond the next 9 to 12 months, some of the higher-rated corporates could face downward pressure.

Strides Shasun to demerge API, exit biotech & probiotic biz

"The structuring is directed towards having a sharper focus on compliance, supply chain and front-ends to provide the necessary growth impetus for its consumer facing formulations business," Strides said.

India's trade deficit with China rises to $53 bn in FY16

During the April-September period of 2016-17, the deficit is at USD 25.22 billion, Commerce and Industry Minister Nirmala Sitharaman said in a written reply to the Lok Sabha.

Will resolve issues raised by USFDA in a timely manner: DRL

The drug major had received a warning letter on November 5, 2015 from the USFDA regarding deviations from current good manufacturing practices (CGMP) at its active pharmaceutical ingredient (API) facilities at Srikakulam, Andhra Pradesh and Miryalaguda in Telangana

Expecting turnover of Rs 250 cr in FY17: NutraPlus

Speaking to CNBC-TV18, Mukesh Naik, MD of NutraPlus told that Cadila, Wanbury, Sun Pharma and Alkem Labs are some of their major clients where the former three contribute 20 percent to the company‘s sales.

Dishman gets licence from J&J to make TB drug raw material

TB is a major concern in India with an estimated 2.8 million cases of the disease. Around 64,000 people have been diagnosed with MDR-TB in the country so far.

Aurobindo Pharma earmarks Rs 900 crore capex for 2015-16

Elaborating on the capital expenditure plans during the current fiscal, he said the company is continuing to invest in enhancing finished dosage as well as active pharmaceutical ingredient (API) capacity.

Revenue to grow at 5-10% in FY16-17: Shilpa Medicare

Vishnukant Bhutada, MD, Shilpa Medicare said sales was low due to expansion and R&D work. He added that the past expansions will start reaping benefits from this year onwards.